30 Participants Needed

Reproductive Health Care Intervention for Young Female Cancer Survivors

Recruiting at 3 trial locations
HI
SR
Overseen BySally Romero, PhD, MPH
Age: < 65
Sex: Female
Trial Phase: Academic
Sponsor: University of California, San Diego
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this pilot study is to evaluate the feasibility of a multi-component intervention to improve young female cancer survivors' engagement in goal-concordant reproductive health care. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant reproductive health care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment for reproductive health care intervention in young female cancer survivors?

Research shows that interventions like peer counseling and couple-based programs can improve sexual function and reproductive health knowledge, which are important for young cancer survivors facing reproductive challenges. These approaches help manage distress and improve quality of life, suggesting that similar interventions could be beneficial for young female cancer survivors.12345

How does the drug Lynparza differ from other treatments for reproductive health care in young female cancer survivors?

Lynparza is unique because it is a targeted therapy known as a PARP inhibitor, which works by preventing cancer cells from repairing their DNA, leading to cell death. This mechanism is different from traditional chemotherapy, which attacks all rapidly dividing cells, and it may offer a more focused approach to addressing reproductive health concerns in cancer survivors.46789

Research Team

HI

H. Irene Su, MD, MSCE

Principal Investigator

University of California, San Diego

Eligibility Criteria

This trial is for young female cancer survivors living in Imperial County, California. They must have been diagnosed with cancer at any stage from 0-IV and be receiving care at a rural oncology clinic participating in the study. Participants need to speak English or Spanish but cannot join if they are pregnant.

Inclusion Criteria

Receiving oncology care at rural oncology clinical participating site
Living in Imperial County, California
My cancer is at any stage from 0 to IV.
See 1 more

Exclusion Criteria

I am currently pregnant.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive a multi-component intervention to improve engagement in goal-concordant reproductive health care

12 weeks
Visits coincide with oncology clinical visits

Follow-up

Participants are monitored for engagement in reproductive health care after the intervention

12 weeks

Treatment Details

Interventions

  • Multi-component reproductive health care intervention
Trial Overview The study is testing a multi-component reproductive health care intervention aimed at improving engagement in reproductive health care that aligns with the goals of young female cancer survivors.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Multi-component interventionExperimental Treatment1 Intervention
After the intervention implementation, all cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive the multi-component intervention.

Multi-component reproductive health care intervention is already approved in European Union, United States for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Lynparza for:
  • Ovarian cancer
  • Breast cancer
  • Fallopian tube cancer
  • Peritoneal cancer
  • Pancreatic cancer
  • Prostate cancer
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Lynparza for:
  • Ovarian cancer
  • Breast cancer
  • Fallopian tube cancer
  • Peritoneal cancer
  • Pancreatic cancer
  • Prostate cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Diego

Lead Sponsor

Trials
1,215
Recruited
1,593,000+

Cancer Resource Center of the Desert

Collaborator

Trials
3
Recruited
260+

El Centro Regional Medical Center

Collaborator

Trials
2
Recruited
110+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

San Diego State University

Collaborator

Trials
182
Recruited
119,000+

Findings from Research

A brief, 4-hour group intervention for 20 young breast cancer survivors significantly improved sexual function and reduced anxiety two months after treatment, highlighting its effectiveness in managing side effects of ovarian suppression.
The intervention combined sexual health rehabilitation, body awareness exercises, and mindfulness-based cognitive therapy, showing moderate-to-large effect sizes in improving both sexual health and psychological well-being.
Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors.Bober, SL., Fine, E., Recklitis, CJ.[2020]
The peer counseling program significantly improved knowledge about reproductive health among African American breast cancer survivors, with a notable increase in understanding reproductive issues from baseline to 3-month follow-up (P < .0001).
Participants also reported reductions in emotional distress (P = .0047) and menopausal symptoms (P = .0128), indicating that the program effectively addressed key concerns related to sexual function and well-being post-treatment.
Randomized trial of peer counseling on reproductive health in African American breast cancer survivors.Schover, LR., Jenkins, R., Sui, D., et al.[2022]
Survival rates for pediatric and adolescent/young adult (AYA) cancer patients have improved to 85%, but over 75% of survivors face long-term adverse effects from treatments, particularly affecting their quality of life.
Infertility and poor reproductive outcomes are significant issues for 12-88% of survivors receiving gonadotoxic therapies, highlighting the need for standard fertility preservation counseling, yet barriers such as lack of knowledge and misconceptions hinder access to these vital interventions.
Disparities in Female Pediatric, Adolescent and Young Adult Oncofertility: A Needs Assessment.Coker Appiah, L., Fei, YF., Olsen, M., et al.[2021]

References

Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors. [2020]
Randomized trial of peer counseling on reproductive health in African American breast cancer survivors. [2022]
Disparities in Female Pediatric, Adolescent and Young Adult Oncofertility: A Needs Assessment. [2021]
Reproductive intentions and use of reproductive health care among female survivors of childhood cancer. [2019]
Opening the Conversation: study protocol for a Phase III trial to evaluate a couple-based intervention to reduce reproductive and sexual distress among young adult breast and gynecologic cancer survivor couples. [2022]
The importance of assessing priorities of reproductive health concerns among adolescent and young adult patients with cancer. [2015]
"Looking at future cancer survivors, give them a roadmap": addressing fertility and family-building topics in post-treatment cancer survivorship care. [2022]
Patient-Centered Communication to Address Young Adult Breast Cancer Survivors' Reproductive and Sexual Health Concerns. [2021]
The need for reproductive and sexual health discussions with adolescent and young adult cancer patients. [2013]